Teva and Alvotech have finally launched their adalimumab biosimilar, Simlandi, in the US. While arriving many months behind their rivals, the partners are hoping that the product’s combination of a citrate-free, 100mg/ml high concentration and an interchangeability designation will position it for success.
Teva and Alvotech have finally reached the end of their long journey to bringing a US Humira (adalimumab) biosimilar to market.
Confirming the launch of their partnered Simlandi (adalimumab-ryvk) version, the firms heralded the product as “first high-concentration, citrate-free biosimilar to Humira with interchangeability exclusivity for the 40mg/0
Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
